- Home
- SHBI vs BCYC Comparison
SHBI vs BCYC Comparison
Compare SHBI & BCYC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Company Overview
Basic Information| Metric | SHBI | BCYC |
|---|---|---|
| Founded | 1876 | 2009 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 541.5M | 438.4M |
| IPO Year | N/A | 2019 |
Fundamental Metrics
Financial Performance| Metric | SHBI | BCYC |
|---|---|---|
| Price | $17.63 | $7.10 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 3 | 11 |
| Target Price | ★ $19.17 | $18.73 |
| AVG Volume (30 Days) | 187.4K | ★ 329.4K |
| Earning Date | 10-23-2025 | 10-30-2025 |
| Dividend Yield | ★ 2.72% | N/A |
| EPS Growth | ★ 38.21 | N/A |
| EPS | ★ 1.71 | N/A |
| Revenue | ★ $212,493,000.00 | $28,339,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | $13.77 | N/A |
| P/E Ratio | $10.36 | ★ N/A |
| Revenue Growth | ★ 10.07 | N/A |
| 52 Week Low | $11.47 | $6.03 |
| 52 Week High | $17.84 | $21.50 |
Technical Indicators
Market Signals| Indicator | SHBI | BCYC |
|---|---|---|
| Relative Strength Index (RSI) | 65.49 | 50.66 |
| Support Level | $17.26 | $6.76 |
| Resistance Level | $17.84 | $7.83 |
| Average True Range (ATR) | 0.40 | 0.42 |
| MACD | 0.12 | 0.10 |
| Stochastic Oscillator | 90.47 | 58.06 |
Price Performance
Historical ComparisonAbout SHBI Shore Bancshares Inc
Shore Bancshares Inc is a financial holding company. It offers personalized banking, insurance, and investment services to families and businesses in the Mid-Atlantic region. It operates in one business segment- banking. The company's primary source of revenue is derived from interest earned on commercial, residential mortgage and other loans, and fees charged in connection with lending and other banking services located in Maryland, Delaware and Virginia.
About BCYC Bicycle Therapeutics plc
Bicycle Therapeutics PLC is a clinical-stage biopharmaceutical company developing a novel class of medicines which are referred to as Bicycles. The Bicycles are synthetic short peptides constrained to form two loops that stabilize their structural geometry. Its initial internal programs are focused on oncology indications with high unmet medical needs. The company's product candidate, BT1718, is a Bicycle Toxin Conjugate, or BTC. The company has two segments: the United Kingdom and the United States. It derives maximum revenue from United States.